Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

Zamarin, Dmitriy; Burger, Robert A.; Sill, Michael W.; Powell, Daniel J.; Lankes, Heather A.; Feldman, Michael D.; Zivanovic, Oliver; Gunderson, Camille C.; Ko, Emily; Mathews, Cara; Sharma, Sudarshan; Hagemann, Andrea R.; Khleif, Samir N.; Aghajanian, Carol

doi:10.1200/jco.19.02059

Cited by 223 publications

(172 citation statements)

References 27 publications

Supporting

Mentioning

166

Contrasting

Unclassified

Order By: Relevance

“…Matulonis [120] Dual immune checkpoint blockade strategies in ovarian cancer have also been investigated. Trial NRG-GY003 evaluated ipilimumab plus nivolumab compared with nivolumab alone in women with persistent or recurrent epithelial ovarian cancer [122]. Subjects were randomized to intravenous nivolumab (every 2 weeks) or induction with nivolumab plus ipilimumab for 4 doses (every 3 weeks), which was followed by maintenance nivolumab every two weeks for a maximum of 42 doses.…”

Section: Immune Checkpoint Inhibition Therapy In Ovarian Cancermentioning

confidence: 99%

Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs

Drakes

Czerlanis

Stiff

2020

Cancers

View full text Add to dashboard Cite

This review provides an update on the current use of immune checkpoint inhibitors (ICI) in female gynecologic cancers, and it addresses the potential of these agents to provide therapy options for disease management and long-term remission in advanced disease patients, where surgery, chemotherapy, and/or radiation fail to meet this goal. The topic of immune checkpoint inhibitors (ICI) blocking cytotoxic T lymphocyte associated protein-4 (CTLA-4) and the programmed death-1 (PD-1) axis has come to the forefront of translational medicine over the last decade for several malignancies. The text will focus primarily on a discussion of ovarian cancer, which is the most frequent cause of death of gynecologic cancers; endometrial cancer, which is the most often diagnosed gynecologic cancer; and cervical cancer, which is the third most common female gynecologic malignancy, all of which unfavorably alter the lives of many women. We will address the critical factors that regulate the outcome of these cancer types to ICI therapy, the ongoing clinical trials in this area, as well as the adverse immune responses that impact the outcome of patients given ICI regimens.

show abstract

Section: Immune Checkpoint Inhibition Therapy In Ovarian Cancermentioning

confidence: 99%

Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs

Drakes

Czerlanis

Stiff

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…7 However, compared with monotherapy CBT, dual blockade treatment of anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) has shown more promising results in the clinic. 112 Understanding the contribution of myeloid cells as immune-stimulatory or immunosuppressive cell types can facilitate the rational design of additional combination treatments.…”

Section: Myeloid Apc In Cbt-resistant Carcinomas Invasive Breast Carcmentioning

confidence: 99%

Impact of anatomic site on antigen-presenting cells in cancer

Zagorulya

Duong

Spranger

2020

J Immunother Cancer

View full text Add to dashboard Cite

Checkpoint blockade immunotherapy (CBT) can induce long-term clinical benefits in patients with advanced cancer; however, response rates to CBT vary by cancer type. Cancers of the skin, lung, and kidney are largely responsive to CBT, while cancers of the pancreas, ovary, breast, and metastatic lesions to the liver respond poorly. The impact of tissue-resident immune cells on antitumor immunity is an emerging area of investigation. Recent evidence indicates that antitumor immune responses and efficacy of CBT depend on the tissue site of the tumor lesion. As myeloid cells are predominantly tissue-resident and can shape tumor-reactive T cell responses, it is conceivable that tissue-specific differences in their function underlie the tissue-site-dependent variability in CBT responses. Understanding the roles of tissue-specific myeloid cells in antitumor immunity can open new avenues for treatment design. In this review, we discuss the roles of tissue-specific antigen-presenting cells (APCs) in governing antitumor immune responses, with a particular focus on the contributions of tissue-specific dendritic cells. Using the framework of the Cancer-Immunity Cycle, we examine the contributions of tissue-specific APC in CBT-sensitive and CBT-resistant carcinomas, highlight how these cells can be therapeutically modulated, and identify gaps in knowledge that remain to be addressed.

show abstract

“…The median PFS was 2 months in the nivolumab group and 3.9 months in the nivolumab plus ipilimumab groups. Compared with nivolumab monotherapy, the combination of nivolumab and ipilimumab in OC resulted in a better response rate and longer PFS [74].…”

Section: Combination Therapy Of Pd-1 Inhibitors With Chemotherapy Andmentioning

confidence: 98%

The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers

Kooshkaki

Derakhshani

Safarpour

et al. 2020

IJMS

View full text Add to dashboard Cite

Gynecologic cancers account for approximately 11% of the newly diagnosed cancers in women in the United States and for 18% globally. The presence of tumor-infiltrating lymphocytes (TILs) influences the clinical outcome of cancer patients and immune checkpoint inhibitors (ICIs), including anti programmed cell death protein-1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), and anticytotoxic T-lymphocyte antigen 4 (anti-CTLA-4), which have been approved for treating different types of malignancies. Antibodies targeting the PD-1/PD-L1 checkpoint have shown dynamic and durable tumor regressions, suggesting a rebalancing of the host–tumor interaction. There are several the US food and drug administration (FDA)-approved ICIs targeting PD-1, including pembrolizumab and nivolumab, as well as those targeting PD-L1, including avelumab, atezolizumab, and durvalumab for melanoma, renal cell cancer, colorectal cancer, head and neck cancer, cervix cancer, urothelial cancer, and lung cancer. Current pre-clinical and clinical studies assessing PD-1/PD-L1 inhibitors in several gynecologic cancers have reported significant antitumor activity. In this review, we investigate pre-clinical and clinical studies that describe the safety and efficacy of anti-PD-1/PD-L1 antibodies, with a particular focus on ongoing clinical trials, analyzing the oncological outcome and adverse effects of ICIs in gynecologic cancers.

show abstract

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

Cited by 223 publications

References 27 publications

Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs

Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs

Impact of anatomic site on antigen-presenting cells in cancer

The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers

Contact Info

Product

Resources

About